A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite High (MSI-H) and Non-MSI-H Colon Cancer

Trial Profile

A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite High (MSI-H) and Non-MSI-H Colon Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Nivolumab (Primary) ; BMS 986016; Cobimetinib; Daratumumab; Ipilimumab
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms CheckMate 142
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 12 Sep 2017 Results of the biomarker analysis (n=84) presented at the 42nd European Society for Medical Oncology Congress
    • 01 Aug 2017 Results published in the Bristol-Myers Squibb media release
    • 01 Aug 2017 According to a Bristol-Myers Squibb media release, Based on the data from this trial the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for intravenous use for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top